EE62 Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed By Adjuvant Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer (ETNBC) in France
Abstract
Authors
L. Cagnan A. Haiderali L. Bensimon B. Tehard M. Carita A. Khandelwal J. Gandhi M. Huang